Render Target: STATIC
Render Timestamp: 2024-10-30T09:49:26.972Z
Commit: 23cb9f61fe67e1e9093fd644a533c4ff516a6463
XML generation date: 2024-08-01 15:28:06.946
Product last modified at: 2024-10-23T19:00:08.304Z
1% for the planet logo
PDP - Template Name: Polyclonal Antibody
PDP - Template ID: *******59c6464

SQLE Antibody #40659

Filter:
  • WB
  • IP

    Supporting Data

    REACTIVITY H
    SENSITIVITY Endogenous
    MW (kDa) 60
    SOURCE Rabbit
    Application Key:
    • WB-Western Blotting 
    • IP-Immunoprecipitation 
    Species Cross-Reactivity Key:
    • H-Human 

    Product Information

    Product Usage Information

    Application Dilution
    Western Blotting 1:1000
    Immunoprecipitation 1:50

    Storage

    Supplied in 10 mM sodium HEPES (pH 7.5), 150 mM NaCl, 100 µg/ml BSA and 50% glycerol. Store at –20°C. Do not aliquot the antibody.

    Protocol

    Specificity / Sensitivity

    SQLE Antibody recognizes endogenous levels of total SQLE protein.

    Species Reactivity:

    Human

    Source / Purification

    Polyclonal antibodies are produced by immunizing animals with a synthetic peptide corresponding to residues surrounding Pro85 of human SQLE protein. Antibodies are purified by protein A and peptide affinity chromatography.

    Background

    Squalene monooxygenase (SQLE), also known as squalene epoxidase, catalyzes the stereospecific oxidation of squalene to (S)-2,3-epoxysqualene (1,2) and is considered to be a critical rate-limiting enzyme in cholesterol biosynthesis downstream of 3-hydroxy-3-methylglutaryl-coenzyme A reductase (HMGCR) (3). The N-terminal region of SQLE is anchored to the endoplasmic reticulum membrane via a re-entrant loop, and undergoes a conformational change in response to elevated cholesterol levels. This cholesterol-mediated conformational change promotes the interaction of SQLE with the E3 ligase MARCH6, leading to targeted ubiquitination and proteasomal degradation (4-6). Altered expression of SQLE is associated with perturbed cholesterol homeostasis and tumor progression, prompting investigation of the therapeutic potential of SQLE (7). Moreover, research studies have shown that cholesterol auxotrophy and subsequent squalene accumulation observed in certain cancers may prevent oxidative cell death and represent a targetable vulnerability to SQLE inhibitors (8,9).
    For Research Use Only. Not For Use In Diagnostic Procedures.
    Cell Signaling Technology is a trademark of Cell Signaling Technology, Inc.
    XP is a registered trademark of Cell Signaling Technology, Inc.
    All other trademarks are the property of their respective owners. Visit our Trademark Information page.